Laekna Acquires Global Rights to Novartis Clinical-Stage PD-L1
publication date: Mar 24, 2020
Laekna Therapeutics Shanghai acquired global rights to Novartis' anti-PD-L1 antibody (FAZ053), the third deal between Laekna and Novartis. In a Phase I trial, FAZ053 demonstrated a tolerable safety profile and clinical efficacy in diverse solid tumors. Laekna plans new trials that combine the PD-L1 with chemotherapies. Previously, Laekna in-licensed global rights from Novartis to a small-molecule tumor treatment, and two oral AKT pan inhibitors. Laekna also conducts R&D on its own in-house projects. In 2019, the company completed a $27.5 million B financing, led by GP Healthcare.
Stock Symbol: (NYSE: NVS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.